Travere Therapeutics (TVTX) Other Operating Expenses (2011 - 2026)
Travere Therapeutics' (TVTX) quarterly Other Operating Expenses came in at $26.8 million in Q1 2026, up 56.49% YoY from $17.1 million in Q1 2025, and up 948.41% on a QoQ basis from $2.6 million in Q4 2025.
Travere Therapeutics (TVTX) Other Operating Expenses (2011 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 16 years of Other Operating Expenses data on file, last reported at $26.8 million in Q1 2026.
- Quarterly Other Operating Expenses rose 56.49% year-over-year to $26.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.4 million (up 38.68% YoY) and the FY2025 annual result came in at $10.3 million, down 85.83% from the prior year.
- Other Operating Expenses improved to $26.8 million in Q1 2026, from $2.6 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $66.7 million in Q1 2024 to a low of -$8.0 million in Q1 2022.
- A 5-year average of $7.2 million and a median of $1.6 million in 2024 frame the typical range for Other Operating Expenses.
- Annual changes were most pronounced in 2022 — Other Operating Expenses tumbled 274.05% — and 2024, when it jumped 1509.38%.
- Tracing TVTX's Other Operating Expenses over 5 years: stood at $868000.0 in 2022, then surged by 425.81% to $4.6 million in 2023, then plunged by 43.23% to $2.6 million in 2024, then retreated by 1.47% to $2.6 million in 2025, then surged by 948.41% to $26.8 million in 2026.
- The last three Other Operating Expenses figures came in at $26.8 million (Q1 2026), $2.6 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.24 Mn |
| Mar 31, 2026 | 26.77 Mn |
| Dec 31, 2025 | 2.55 Mn |
| Sep 30, 2025 | 1.59 Mn |
| Jun 30, 2025 | 1.52 Mn |
| Mar 31, 2025 | 17.10 Mn |
| Dec 31, 2024 | 2.59 Mn |
| Sep 30, 2024 | 1.63 Mn |
| Jun 30, 2024 | 2.06 Mn |
| Mar 31, 2024 | 66.71 Mn |
| Dec 31, 2023 | 4.56 Mn |
| Sep 30, 2023 | 1.29 Mn |
| Jun 30, 2023 | 1.45 Mn |
| Mar 31, 2023 | 4.15 Mn |
| Dec 31, 2022 | 868,000.00 |
| Sep 30, 2022 | 1.11 Mn |
| Jun 30, 2022 | -5.50 Mn |
| Mar 31, 2022 | -8.01 Mn |
| Dec 31, 2021 | -25.03 Mn |
| Sep 30, 2021 | 15.46 Mn |